Meda acquires OTC products in the US

Meda has acquired three well established Over-The-Counter consumer products in the US from GlaxoSmithKline LLC (“GSK”). Total annual sales for the products are about 100 MSEK, with strong profit margins. The purchase price was 235 MSEK.

”These well known consumer brands strengthen our OTC business in the US”, said Anders Lönner, CEO Meda.

Meda and GSK are also pursuing further discussions on additional OTC acquisitions in the US market.

For questions, please contact:

Anders Larnholt, Vice President Corporate Development & IR      ph: +46 709-458 878
 

MEDA AB (publ) is a leading international specialty pharma company. Meda’s products are sold in 120 countries worldwide and the company is represented by its own organizations in 50 countries. The Meda share is listed under Large Cap on the Nasdaq OMX Nordic Stock Exchange in Stockholm. Find out more, visit www.meda.se.

Meda acquires OTC products in the US Meda AB (publ), corporate ID: 556427-2812 Pipers väg 2A, Box 906, SE-170 09 Solna, Sweden info@meda.se, www.meda.se,
Tel: +46-8-630 19 00. Fax: +46-8-630 19 50

---